Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
18 Years and older, Male and Female
VT3996-201 (primary)
NCI-2018-00416
Summary
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in
combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this
combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+
lymphomas).
Objectives
The purpose of this study is to determine whether VRx-3996 in combination with
valganciclovir is safe, determine the side effect profile, and to determine whether this
therapy may help patients with EBV-related lymphomas. The study has two phases. Goals of
the first phase include determining a safe and tolerable dose that can be administered in
phase 2. Goals of the second phase include further evaluating the safety and tolerability
of VRx-3996 in combination with valganciclovir, evaluating how the drugs are metabolized
in the body, evaluating response rates and other exploratory objectives that will help
the researchers evaluate how these drugs work in the body. Participants will receive
daily oral doses of the two study drugs and will have multiple study visits where they
will have blood collected, physical examinations, and other medical monitoring. Following
completion of the Ph2, the study will enroll additional patients into a Tablet
Pharmacokinetic (PK) cohort to investigate the PK parameters of the tablet formulation.
Eligibility
- Relapsed/refractory, pathologically confirmed Epstein-Barr Virus positive (EBV+) lymphoid malignancy or lymphoproliferative disease
- Absence of available therapy with reasonable likelihood of cure or significant clinical benefit
- Adequate hematologic, hepatic and renal function as defined by laboratory assessment Key
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.